Boyds has joined CTD Holdings’ International Clinical Program team, along with Aptus Clinical and KJC Statistics, to develop orphan drug Trappsol Cyclo with Accenture.
CTD Holdings is a family of biotechnology companies that develop cyclodextrin-based treatments and other products. Together, clinical research specialists Accenture, Aptus, Boyds and KJC bring strong international experience to CTD's orphan drug development programme.
Trappsol Cyclo is used for the treatment of *Niemann-Pick Type C, a rare and often fatal genetic disease that occurs primarily in young children. The company holds orphan designation for Trappsol Cyclo in Europe and is obtaining orphan drug designation in the US. It is currently being used as an investigational new drug on a compassionate use or named patient basis in Europe, Brazil and the US.
Professor Alan Boyd, CEO and Founder of Boyds, said: "Together our group has extensive experience in the development and commercialisation of orphan drugs. We are delighted to bring this experience to CTD's International Clinical Program for Trappsol Cyclo, which is being developed for a clear, unmet medical need."
President and CEO of CTD Holdings Dr. Jeffrey Tate added: "We have assembled a powerful team for our International Clinical Program. The addition of Aptus, Boyds and KJC reflects our commitment to completing clinical trials quickly and making Trappsol Cyclo available to Niemann-Pick Type C patients around the world."
All parties have signed contracts and the project is now underway.
*Niemann-Pick Type C (NP-C) disease is a rare genetic disease where fatty molecules slowly build up in the body to levels that can eventually cause serious problems. NP-C affects infants, children and adults and affects about one in every 120,000 births worldwide.